Relationship between body surface area and ALT normalization after long-term lamivudine treatment

Table 7 Baseline characteristics of patients treated for 3 years

	Total (range)	SR-ALT	NR-AL	SR-DNA	NR-DNA
n	72	33	39	38	34
Male/female	53/19	21/12	32/7	27/11	26/8
ALT (U/L)	198.6±437.2 (18-3545)	200.0±229.0	197.5±562.1	191.2±218.0	207.2±602.6
Albumin (g/dL)	3.8±0.5 (2.5-4.9)	3.7±0.4	4.0±0.5	3.8±0.5	3.9±0.5
Bilirubin (mg/dL)	1.5±2.1 (0.3-12.9)	1.6±2.2	1.5±2.3	1.6±2.2	1.5±2.4
Platelet (104/mL)	13.8±6.2 (3.9-33.6)	11.6±4.6	15.1±6.9	13.3±5.8	13.8±6.5
BSA (m2)	1.71±0.18 (1.30-2.17)	1.75±0.17	1.66±0.19	1.69±0.17	1.73±0.20
HBV-DNA
≤5 (LEG/mL)	7	4	3	4	3
5< ≤6	15	4	11	6	9
6< ≤7	17	11	6	13	4
7<	33	14	19	15	18
HBeAg +/–	41/31	12/21	20/19	22/16	19/15
Age (yr)	49.5±11.1 (21-73)
CH/LC [Child A/B/C]	43/29 [25/0/4]

¹ Data are shown as mean±SD.